H.C. Wainwright Reiterates Buy Rating on Zevra Therapeutics, Inc. (ZVRA)

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $26.00 price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA).

The analyst commented: "On 12/29 ZVRA announced that the company has signed an exclusive expanded access distribution agreement with Uniphar that adds new territories to ZVRA's current expanded access program for Miplyffa (arimoclomol) for Niemann-Pick Disease Type C patients. We believe the opportunity for Miplyffa announced today is not priced into ZVRA stock or consensus expectations and represents upside to our forecasts. Reiterate Buy and $26 PT."

For an analyst ratings summary and ratings history on Zevra Therapeutics, Inc. click here. For more ratings news on Zevra Therapeutics, Inc. click here.

Shares of Zevra Therapeutics, Inc. closed at $8.82 yesterday.

You May Also Be Interested In

• BofA Securities Starts Kanzhun Ltd. (BZ) at Neutral
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
• BofA Securities Starts Definium Therapeutics Inc (DFTX) at Buy